Two articles on FTY720.
Novartis Pharmaceuticals initiates new world-wide Phase III study for Fingolimod (FTY720)
Following a two-year phase II clinical study, in which Novartis Pharmaceuticals reported a relapse rate reduction of more then 50%, compared to placebo, with 77% of people taking Fingolimod (FTY720) remaining relapse-free over two years. Novartis has announced the initiation of a world-wide Phase III study in more than 3000 people with MS.
The FREEDOMS multi-centre study, is to ...